Literature DB >> 1378212

Mapping of a B-cell epitope present in the neuraminidase of Trypanosoma cruzi.

R P Prioli1, E Ortega-Barria, J S Mejia, M E Pereira.   

Abstract

We have previously shown that a polyclonal (rabbit anti-TCNA) and a mouse monoclonal antibody (TCN-2) against the neuraminidase of Trypanosoma cruzi (TCNA) inhibit enzyme activity, immunoprecipitate active enzyme, enhance in vitro infection, and identify a subpopulation of extracellular trypomastigotes. We now report on the identification of a synthetic peptide that contains the epitope recognized by these antibodies. The synthetic peptide (TR) is a dodecamer (D-S-S-A-H-G-T-P-S-T-P-A) deduced from the DNA sequence of the long tandem repeat (LTR) domain present in the TCNA carboxyterminus. By ELISA, rabbit anti-TCNA bound to TR coupled to ovalbumin, and the binding was inhibited by soluble TR but not by BR (Y-S-V-D-D-G-E-T-W-E), a peptide derived from the N-terminal domain of the enzyme. TCN-2 recognized TR, and this reaction as well as TCN-2 binding to endogenous TCNA could be inhibited by soluble TR but not by BR. These results indicate that the rabbit anti-TCNA and TCN-2 react with the LTR region of TCNA. Antibodies to TR reacted by immunoblot with the TCNA of the Silvio X-10/4, MV-13 and Y-H6 strains, identifying the same molecular polymorphism previously observed with the rabbit anti-TCNA and TCN-2. Furthermore, anti-TR antibodies immunoprecipitated active enzyme and immunofluorescence analysis revealed that anti-TR and TCN-2 antibodies detected equally well the differential expression of their epitopes in intra- and extracellular trypomastigotes. Moreover, expression of TR and TCN-2 epitopes on the different stages of T. cruzi paralleled the stage-specificity of TCNA activity. TCN-2 prevented desialylation by TCNA of intact cells but not of soluble glycoconjugates, indicating that TCN-2 epitope is probably not associated with the enzyme catalytic site, in agreement with the predicted sequence of the TCNA gene. Finally, analysis of the humoral response of a Chagasic patient to different areas of the TCNA molecule indicated that the antibody response is predominantly against TR suggesting that the tandem repeat is the immunodominant domain of TCNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378212     DOI: 10.1016/0166-6851(92)90038-l

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  8 in total

1.  Multiple overlapping epitopes in the repetitive unit of the shed acute-phase antigen from Trypanosoma cruzi enhance its immunogenic properties.

Authors:  P Alvarez; M S Leguizamón; C A Buscaglia; T A Pitcovsky; O Campetella
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.

Authors:  M E Pereira; K Zhang; Y Gong; E M Herrera; M Ming
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

3.  Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence.

Authors:  M Belen Carrillo; W Gao; M Herrera; J Alroy; J B Moore; S M Beverley; M A Pereira
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

4.  Mice infected with Trypanosoma cruzi produce antibodies against the enzymatic domain of trans-sialidase that inhibit its activity.

Authors:  M S Leguizamón; O E Campetella; S M González Cappa; A C Frasch
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Identification of a developmentally regulated sialidase in Eimeria tenella that is immunologically related to the Trypanosoma cruzi enzyme.

Authors:  J L Pellegrin; E Ortega-Barria; R P Prioli; M Buerger; R G Strout; J Alroy; M E Pereira
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

6.  Sera from chronic Chagasic patients and rodents infected with Trypanosoma cruzi inhibit trans-sialidase by recognizing its amino-terminal and catalytic domain.

Authors:  V L Pereira-Chioccola; S Schenkman; J K Kloetzel
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

Review 7.  Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids.

Authors:  Edio Maldonado; Sebastian Morales-Pison; Fabiola Urbina; Aldo Solari
Journal:  Vaccines (Basel)       Date:  2022-04-12

8.  Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.

Authors:  M Chuenkova; M E Pereira
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.